Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity
The effect of isoniazid on proliferative response, natural killer (NK) cell activity and lymphocyte subset distribution of blood mononuclear cells (BMNC) was investigated. To evaluate the effect of treatment with isoniazid in pharmacologic concentrations, twenty healthy HIV-seronegative volunteers w...
Gespeichert in:
| Veröffentlicht in: | Immunopharmacology 1995-09, Vol.30 (3), p.247-253 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 253 |
|---|---|
| container_issue | 3 |
| container_start_page | 247 |
| container_title | Immunopharmacology |
| container_volume | 30 |
| creator | Ravn, Pernille Linnet, Jane Klokker, Mads Pedersen, Bente Klarlund |
| description | The effect of isoniazid on proliferative response, natural killer (NK) cell activity and lymphocyte subset distribution of blood mononuclear cells (BMNC) was investigated. To evaluate the effect of treatment with isoniazid in pharmacologic concentrations, twenty healthy HIV-seronegative volunteers were randomized into two groups: one group received isoniazid tablets plus pyridoxin tablets once a day for 30 days, the other group received pyridoxin only. Blood samples were collected on day 0 and day 30. Inhibition of the PHA-induced proliferative response was demonstrated in lymphocyte cultures from isoniazid-treated volunteers (p< 0.001). However, no effect was seen on the IL-2- or antigen (PPD)-induced proliferative response or the NK cell activity of isolated BMNC. Inhibition of the PHA-induced proliferative response could not be related to changes in the distribution of CD3 + , CD4 + , CD8 + , CD14, or CD19 + lymphocyte subsets. The effects, in vitro, were investigated by addition of isoniazid to cultures of BMNC isolated from either HIV-seroposive or HIV-seronegalive donors who did not receive any treatment. We found that isoniazid did not influence the mitogen- or antigen-stimulated proliferative response or the NK cell activity. |
| doi_str_mv | 10.1016/0162-3109(95)00029-S |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77786372</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>016231099500029S</els_id><sourcerecordid>77786372</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-56f5fd238e79840b0ccb4691cdce84d845ece4ce21b032e342b188db657fde633</originalsourceid><addsrcrecordid>eNqFkU9rFTEUxbNQaq1-A4UsRCo4mmSSTGYjSKl_oOCiug6Z5IZGZ5Jnkim8LvrZzfM9Hq7qIgRyfvfkcA9CLyh5RwmV79thXU_JeD6KN4QQNnbXj9Dp8fkJelrKzybwYRQn6EQJMQgmTtH9pfdga8HJ41BSDOYuOFwzmLpArDhFfLMuJuJ5u2xukt1WwJuc5uAhmxpuAWcomxQLvP0XKetUoLma6HA0dc1mxr_CPEPGFuYZG9tmQ90-Q4-9mQs8P9xn6Meny-8XX7qrb5-_Xny86iynQ-2E9MI71isYRsXJRKyduBypdRYUd4oLsMAtMDqRnkHP2USVcpMUg3cg-_4Mvd77tuy_VyhVL6HskpgIaS16GAYl-4H9F6RyHCmTsoF8D9qcSsng9SaHxeStpkTvOtG75evd8vUo9N9O9HUbe3nwX6cF3HHoUEjTXx10U6yZfTbRhnLE-vZ9L1XDPuwxaEu7DZB1sQGiBRdyq1O7FB7O8Qetdq2J</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16991266</pqid></control><display><type>article</type><title>Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ravn, Pernille ; Linnet, Jane ; Klokker, Mads ; Pedersen, Bente Klarlund</creator><creatorcontrib>Ravn, Pernille ; Linnet, Jane ; Klokker, Mads ; Pedersen, Bente Klarlund</creatorcontrib><description>The effect of isoniazid on proliferative response, natural killer (NK) cell activity and lymphocyte subset distribution of blood mononuclear cells (BMNC) was investigated. To evaluate the effect of treatment with isoniazid in pharmacologic concentrations, twenty healthy HIV-seronegative volunteers were randomized into two groups: one group received isoniazid tablets plus pyridoxin tablets once a day for 30 days, the other group received pyridoxin only. Blood samples were collected on day 0 and day 30. Inhibition of the PHA-induced proliferative response was demonstrated in lymphocyte cultures from isoniazid-treated volunteers (p< 0.001). However, no effect was seen on the IL-2- or antigen (PPD)-induced proliferative response or the NK cell activity of isolated BMNC. Inhibition of the PHA-induced proliferative response could not be related to changes in the distribution of CD3 + , CD4 + , CD8 + , CD14, or CD19 + lymphocyte subsets. The effects, in vitro, were investigated by addition of isoniazid to cultures of BMNC isolated from either HIV-seroposive or HIV-seronegalive donors who did not receive any treatment. We found that isoniazid did not influence the mitogen- or antigen-stimulated proliferative response or the NK cell activity.</description><identifier>ISSN: 0162-3109</identifier><identifier>DOI: 10.1016/0162-3109(95)00029-S</identifier><identifier>PMID: 8557525</identifier><identifier>CODEN: IMMUDP</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antitubercular Agents - pharmacology ; Biological and medical sciences ; Female ; HIV ; human immunodeficiency virus ; Humans ; Immunomodulation ; Isoniazid ; Isoniazid - pharmacology ; Killer Cells, Natural - drug effects ; Lymphocyte Activation - drug effects ; Lymphocyte Subsets - drug effects ; Male ; Medical sciences ; Natural killer cell ; Pharmacology. Drug treatments ; Prophylaxis ; Pyridoxine - pharmacology ; Tuberculosis</subject><ispartof>Immunopharmacology, 1995-09, Vol.30 (3), p.247-253</ispartof><rights>1995</rights><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-56f5fd238e79840b0ccb4691cdce84d845ece4ce21b032e342b188db657fde633</citedby><cites>FETCH-LOGICAL-c417t-56f5fd238e79840b0ccb4691cdce84d845ece4ce21b032e342b188db657fde633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3699368$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8557525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ravn, Pernille</creatorcontrib><creatorcontrib>Linnet, Jane</creatorcontrib><creatorcontrib>Klokker, Mads</creatorcontrib><creatorcontrib>Pedersen, Bente Klarlund</creatorcontrib><title>Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity</title><title>Immunopharmacology</title><addtitle>Immunopharmacology</addtitle><description>The effect of isoniazid on proliferative response, natural killer (NK) cell activity and lymphocyte subset distribution of blood mononuclear cells (BMNC) was investigated. To evaluate the effect of treatment with isoniazid in pharmacologic concentrations, twenty healthy HIV-seronegative volunteers were randomized into two groups: one group received isoniazid tablets plus pyridoxin tablets once a day for 30 days, the other group received pyridoxin only. Blood samples were collected on day 0 and day 30. Inhibition of the PHA-induced proliferative response was demonstrated in lymphocyte cultures from isoniazid-treated volunteers (p< 0.001). However, no effect was seen on the IL-2- or antigen (PPD)-induced proliferative response or the NK cell activity of isolated BMNC. Inhibition of the PHA-induced proliferative response could not be related to changes in the distribution of CD3 + , CD4 + , CD8 + , CD14, or CD19 + lymphocyte subsets. The effects, in vitro, were investigated by addition of isoniazid to cultures of BMNC isolated from either HIV-seroposive or HIV-seronegalive donors who did not receive any treatment. We found that isoniazid did not influence the mitogen- or antigen-stimulated proliferative response or the NK cell activity.</description><subject>Adult</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>HIV</subject><subject>human immunodeficiency virus</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Isoniazid</subject><subject>Isoniazid - pharmacology</subject><subject>Killer Cells, Natural - drug effects</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocyte Subsets - drug effects</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Natural killer cell</subject><subject>Pharmacology. Drug treatments</subject><subject>Prophylaxis</subject><subject>Pyridoxine - pharmacology</subject><subject>Tuberculosis</subject><issn>0162-3109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9rFTEUxbNQaq1-A4UsRCo4mmSSTGYjSKl_oOCiug6Z5IZGZ5Jnkim8LvrZzfM9Hq7qIgRyfvfkcA9CLyh5RwmV79thXU_JeD6KN4QQNnbXj9Dp8fkJelrKzybwYRQn6EQJMQgmTtH9pfdga8HJ41BSDOYuOFwzmLpArDhFfLMuJuJ5u2xukt1WwJuc5uAhmxpuAWcomxQLvP0XKetUoLma6HA0dc1mxr_CPEPGFuYZG9tmQ90-Q4-9mQs8P9xn6Meny-8XX7qrb5-_Xny86iynQ-2E9MI71isYRsXJRKyduBypdRYUd4oLsMAtMDqRnkHP2USVcpMUg3cg-_4Mvd77tuy_VyhVL6HskpgIaS16GAYl-4H9F6RyHCmTsoF8D9qcSsng9SaHxeStpkTvOtG75evd8vUo9N9O9HUbe3nwX6cF3HHoUEjTXx10U6yZfTbRhnLE-vZ9L1XDPuwxaEu7DZB1sQGiBRdyq1O7FB7O8Qetdq2J</recordid><startdate>19950901</startdate><enddate>19950901</enddate><creator>Ravn, Pernille</creator><creator>Linnet, Jane</creator><creator>Klokker, Mads</creator><creator>Pedersen, Bente Klarlund</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19950901</creationdate><title>Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity</title><author>Ravn, Pernille ; Linnet, Jane ; Klokker, Mads ; Pedersen, Bente Klarlund</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-56f5fd238e79840b0ccb4691cdce84d845ece4ce21b032e342b188db657fde633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Adult</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>HIV</topic><topic>human immunodeficiency virus</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Isoniazid</topic><topic>Isoniazid - pharmacology</topic><topic>Killer Cells, Natural - drug effects</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocyte Subsets - drug effects</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Natural killer cell</topic><topic>Pharmacology. Drug treatments</topic><topic>Prophylaxis</topic><topic>Pyridoxine - pharmacology</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ravn, Pernille</creatorcontrib><creatorcontrib>Linnet, Jane</creatorcontrib><creatorcontrib>Klokker, Mads</creatorcontrib><creatorcontrib>Pedersen, Bente Klarlund</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ravn, Pernille</au><au>Linnet, Jane</au><au>Klokker, Mads</au><au>Pedersen, Bente Klarlund</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity</atitle><jtitle>Immunopharmacology</jtitle><addtitle>Immunopharmacology</addtitle><date>1995-09-01</date><risdate>1995</risdate><volume>30</volume><issue>3</issue><spage>247</spage><epage>253</epage><pages>247-253</pages><issn>0162-3109</issn><coden>IMMUDP</coden><abstract>The effect of isoniazid on proliferative response, natural killer (NK) cell activity and lymphocyte subset distribution of blood mononuclear cells (BMNC) was investigated. To evaluate the effect of treatment with isoniazid in pharmacologic concentrations, twenty healthy HIV-seronegative volunteers were randomized into two groups: one group received isoniazid tablets plus pyridoxin tablets once a day for 30 days, the other group received pyridoxin only. Blood samples were collected on day 0 and day 30. Inhibition of the PHA-induced proliferative response was demonstrated in lymphocyte cultures from isoniazid-treated volunteers (p< 0.001). However, no effect was seen on the IL-2- or antigen (PPD)-induced proliferative response or the NK cell activity of isolated BMNC. Inhibition of the PHA-induced proliferative response could not be related to changes in the distribution of CD3 + , CD4 + , CD8 + , CD14, or CD19 + lymphocyte subsets. The effects, in vitro, were investigated by addition of isoniazid to cultures of BMNC isolated from either HIV-seroposive or HIV-seronegalive donors who did not receive any treatment. We found that isoniazid did not influence the mitogen- or antigen-stimulated proliferative response or the NK cell activity.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>8557525</pmid><doi>10.1016/0162-3109(95)00029-S</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0162-3109 |
| ispartof | Immunopharmacology, 1995-09, Vol.30 (3), p.247-253 |
| issn | 0162-3109 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77786372 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antitubercular Agents - pharmacology Biological and medical sciences Female HIV human immunodeficiency virus Humans Immunomodulation Isoniazid Isoniazid - pharmacology Killer Cells, Natural - drug effects Lymphocyte Activation - drug effects Lymphocyte Subsets - drug effects Male Medical sciences Natural killer cell Pharmacology. Drug treatments Prophylaxis Pyridoxine - pharmacology Tuberculosis |
| title | Effects of isoniazid treatment on human lymphocyte proliferative response, lymphocyte subsets and natural killer cell activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T06%3A43%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20isoniazid%20treatment%20on%20human%20lymphocyte%20proliferative%20response,%20lymphocyte%20subsets%20and%20natural%20killer%20cell%20activity&rft.jtitle=Immunopharmacology&rft.au=Ravn,%20Pernille&rft.date=1995-09-01&rft.volume=30&rft.issue=3&rft.spage=247&rft.epage=253&rft.pages=247-253&rft.issn=0162-3109&rft.coden=IMMUDP&rft_id=info:doi/10.1016/0162-3109(95)00029-S&rft_dat=%3Cproquest_cross%3E77786372%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16991266&rft_id=info:pmid/8557525&rft_els_id=016231099500029S&rfr_iscdi=true |